INTRODUCTION
Organometallic complexes have emerged in recent years as promising anticancer metallodrugs, which could well overcome cisplatin and platinum-related analogues' disadvantages, mainly toxicity and drug resistance in cancer cells. [1] [2] [3] [4] [5] Among them, ruthenium(II) complexes bearing a π-bonded arene ligand are particularly interesting since they have shown promising anticancer activities, [6] [7] [8] even in cells that had become resistant to cisplatin, such as Sadler's compounds containing N,N-chelating ligands. 1, 9, 10 In addition, some of the Dyson's RAPTA compounds containing pta ligand have shown antimetastatic activity. 11, 12 Their so-called "piano-stool" geometry includes an arene unit that stabilizes the ruthenium +2 oxidation state and confers hydrophobicity on the global metal complex, as well as mono-or bidentate ligands, including one or two leaving groups. In most cases, the release of labile chlorido ligands is triggered inside the cell nucleus by the low chloride concentration (4 mM vs ∼100 mM in extracellular fluids), allowing for the generation of the activated aqua species that possess the capacity to react with the biological target. 13, 14 Ruthenium offers several advantages over platinum compounds, including reduced toxicity and the possibility of controlling the shape and the chemical and pharmacological properties of the complex by the adequate selection of the arene and the ligands at the "legs" of the "piano-stool" structure. 15, 16 Moreover, modification of the non-leaving ligands allows the metal complex to be anchored to a "tumor-targeting device" such as receptor-binding peptides, folic acid or estrogens. [17] [18] [19] [20] [21] [22] [23] [24] This targeted strategy has a tremendous potential in the development of more efficient, less toxic, selective metallodrugs in chemotherapy because receptors for these carrier molecules are over-expressed in the membrane of tumoral cells. [25] [26] [27] [28] Another strategy to improve efficiency of a metal-based drug is to increase its affinity with its ultimate biological target. This strategy has been explored mainly with platinum complexes through the covalent attachment to compounds with high affinity for DNA (minor groove binders or intercalators) or to synthetic oligonucleotides or Peptide
Nucleic Acids complementary to specific DNA sequences. 29 The cytotoxicity of ruthenium(II) arene complexes, like that of platinum compounds, has been attributed mainly to the binding of their aquation products to DNA. 7, 8 However, these complexes' interaction with other potential cellular competitors such as the tripeptide glutathione cannot be ruled out, since they are present in large intracellular concentrations and are responsible for the detoxification of heavier transition metals. 30 In fact, recent studies have revealed that DNA is not always the primary target for some ruthenium anticancer compounds and that they actually bind more strongly to proteins or enzymes than to DNA. 4, 31 Hence, it seems important not only to develop efficient targeting strategies to deliver metallodrugs selectively into cancer cells, but also to direct them towards a particular biological target.
Although, traditionally, metal-based drugs have been designed to target DNA, in therapeutic terms, RNA offers several advantages over DNA as a drug target, since it is involved in many cellular processes, from the regulation of gene expression to protein synthesis. [32] [33] [34] [35] In addition, like proteins, RNA adopts complex three-dimensional structures that can be exploited to design specific small molecules to modulate its functions. [36] [37] [38] In recent years, microRNAs (miRNAs) have also emerged as new therapeutic targets for cancer therapy since the abnormal expression of these non-coding small RNAs is associated with the pathogenesis of human cancer. 39, 40 Like other RNAs, miRNA precursors adopt secondary structures that can be targeted with small molecules, to interfere with miRNA maturation and, for instance, to manipulate miRNA levels. 41, 42 With the aim of developing new metal-based anticancer drugs that could act at the level of RNA, we focused on the conjugation of ruthenium(II) arene complexes with small molecules that had the capacity to recognize selectively RNA over DNA or proteins.
Aminoglycoside antibiotics are possibly the most commonly studied RNA ligands, 33, 36, 43, 44 since they have a relatively high affinity with RNA structures and are able to discriminate A-type from B-type duplexes. 43, 44 Apart from their selectivity for RNA, aminoglycosides possess several amino functions that are mostly protonated under physiological conditions, which would confer some drug-like properties on the metal complex, such as aqueous solubility. However, aminoglycoside antibiotics are known to have a more inefficient uptake by eukaryotic than by prokaryotic cells. 45 This problem has been solved by replacing their amine functions with guanidinium groups to generate guanidinoglycosides, 46 since these derivatives have higher efficient uptake by eukaryotic cells than their aminoglycoside precursors. 45 In fact, guanidinylated neomycin is known to transport bioactive, high molecular weight cargo into the interior of cells. [47] [48] [49] Like naturally occurring aminoglycosides, guanidinoglycosides bind RNA over DNA preferentially, but they have shown higher binding affinity and selectivity against several RNA targets. 46, 50 24 where Im-BzCOOMe refers to the methyl ester of the 4-(1H-imidazol-1-yl)benzoic acid, and neomycin B (2), guanidinoneomycin B (3) and neamine (4) (Scheme 1). In all cases, the metal complex was attached to the amino-or the guanidinoglycoside through the phenyl ring linked to the imidazole ligand. The triphenylphosphine-containing ruthenium(II) complex 1 was recently described as a promising anticancer lead compound, since its anti-proliferative activity is comparable to that of cisplatin in two tumoral cell lines, MCF-7 and DU-145. 24 Interestingly, a direct correlation was found between the cytotoxicity of its octreotide conjugate and the level of expression of the receptors for this peptide in the membrane of tumoral cells. Analytical reversed-phase HPLC analyses were carried out on a GraceSmart RP C 18 column (250x4 mm, 5 µm, flow rate: 1 mL/min), using linear gradients of 0.045% TFA in H 2 O (solvent A) and 0.036% TFA in ACN (solvent B). Large-scale purification was carried out in a Jupiter Proteo semipreparative column (250 x 10 mm, 10 µm, flow rate:
3-4 mL/min), using linear gradients of 0.1% TFA in H 2 O (solvent A) and 0.1% TFA in ACN (solvent B). After several runs, pure fractions were combined and lyophilized.
A [Vydac C18]-filled glass column (22x2 cm, 15-20 mm, 300 Å) was used for mediumpressure liquid chromatography (MPLC), using aqueous and ACN solutions containing 0.05% TFA (flow rate: 3 mL/min). Elution was carried out by connecting a piston pump to the mixing chamber of a gradient-forming device and to the top of the glass column.
The mixing chamber of the gradient-forming device was the flask containing solvent A, which was connected through a stopcock to the flask containing solvent B. The bottom of the preparative column was connected to an automatic fraction collector through a UV/Vis detector, which was also connected to a chart recorder using the appropriate ports. The column was equilibrated with 200 mL of solvent A, and 600 mL of each mobile phase was introduced into the appropriate compartments of the gradient-forming device. 
Synthesis and characterization of conjugates
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Cytotoxicity assays in cancer cell lines
The cytotoxicity of the conjugates and of the control compounds was determined by the 
RESULTS
Synthesis and characterization of ruthenium-amino(guanidino)glycoside conjugates.
Conjugation of the ruthenium complex to neomycin B was planned through the 5''-OH, since this primary hydroxyl group can be regioselectively converted to amino group, allowing the attachment of the imidazole ligand via an amide bond formation. In addition, this modification does not alter the number of chargeable groups that are essential for RNA binding and cell uptake. First, 4-(1H-Imidazol-1-yl)benzoic acid was coupled with the Boc-protected amino derivative of neomycin 52 (5, Scheme 2) by using
PyBOP as a coupling reagent in anhydrous DMF for 2 h at rt in the presence of DIPEA.
The metal complex was assembled on the imidazole-derivatized neomycin (6) High-resolution ESI MS analysis of the neomycin-ruthenium conjugate 2 afforded an m/z value that was consistent with the calculated value of the monocharged species
and with the expected isotopic distribution of ruthenium ( Figure 1 ). In addition, The reaction was very slow, especially the incorporation of the sixth guanidinium group, as followed by ESI MS analysis. Once the reaction reached completion (about 20 days), the Boc-protected guanidino conjugate was treated with a TFA/DCM mixture (1:1) for 4 h at RT. Reversed-phase HPLC analysis revealed the presence of a main peak, which was isolated and characterized by high-resolution MS and NMR as the expected conjugate 3 (overall yield from 2: 34%). It is interesting to note that the ruthenium complex remained unaltered during the prolonged reaction time, which accounts for its high stability in solution (see below).
One of the main problems of aminoglycoside antibiotics is their inherent toxicity, usually nephrotoxicity or ototoxicity, which are associated with non-specific electrostatic binding to RNA. 43, 44 To minimize these problems, we selected the pseudodisaccharide known as neamine (Scheme 1), because a reduction in the number The attachment of the metal complex was planned through the 5-hydroxyl group of the 2-deoxystreptamine ring (Scheme 1), since the use of trityl protective groups for the amino functions allows the regioselective protection of all hydroxyl functions with 4-methoxybenzyl groups, except that located at the 5-position. 53 Again, the required imidazole-derivatized neamine (9) was obtained by reaction between 4-(1H-Imidazol-1-yl)benzoic acid and the (Trt) 4 (PMB) 3 -protected amino derivative of neamine (8) 
Studies on the activation of the ruthenium complex in conjugates 2 and 3
Since the cytotoxic activity of most metallodrugs is intimately related to their hydrolysis behavior in aqueous media, prior to cytotoxicity studies we wanted to assess whether hydrolysis of the Ru-Cl bond occurs when the ruthenium complex is conjugated to the glycoside carrier. This process is known to facilitate the interaction of the metal with the biological target (e.g. nucleic acids or proteins) through the generation of monofunctional adducts on guanine nucleobases by the activated aqua species.
Although anticancer activity of ruthenium(II) arene complexes has been attributed in most cases to DNA ruthenation, some compounds such as 1 do not experience aqueous hydrolysis of the Ru-Cl bond, 24 which hinders the covalent interaction with the biological target.
On the basis of these precedents, the stability of conjugates 2 and 3 (Scheme 1) was investigated in aqueous solution at a chloride concentration mimicking the typical cell nucleus (4 mM). As previously found with 1 or its peptide conjugate, 24 reversed-phase HPLC analysis together with MS revealed that no hydrolysis occurred in the case of the ruthenium-(guanidino)neomycin conjugates on incubation at 37ºC for 48 h.
Surprisingly, the compounds also remained unaltered upon incubation at 37ºC for 72 h with a large excess of glutathione (250 mol equiv) under physiologically relevant conditions (pH 7 phosphate buffer containing 22 mM NaCl, the cytoplasmatic concentration of chloride). 30 These results suggest that the ruthenium moiety in the amino(guanidino)glycoside conjugates (2-4) does not follow the typical activation mechanisms of most organometallic anticancer complexes (e.g. hydrolysis of the Ru-Cl bond and/or redox activation through the participation of the tripeptide glutathione). The concentration-response curves, plotted in Figure 2 , revealed that the cytotoxic activity of conjugates 2-4 was very dependent on the nature of the glycoside moiety in these cell lines. As previously reported, 24 To assess the conjugates' selectivity for tumor cells rather than normal cells, we determined the cell viability of a non-tumorigenic HEK293 cell line, in the presence of conjugates 2-4. To our surprise, ruthenium complex 1 (IC 50 = 2.50 µM) was found more cytotoxic in the normal cell line than in the two cancer cell lines, whereas cisplatin cytotoxicity was similar (IC 50 = 4.63 µM) (Table 1) . Again, control aminoglycosides and guanidinoneomycin were found to be non-cytotoxic (IC 50 > 250). As shown in Figure 2, the cytotoxicity of the ruthenium-glycoside conjugates against HEK293 cells can be ranked in the following order: 3 >> 2 > 4, which reproduces the tendency found in cancer cell lines. Interestingly, although control complex 1 and aminoglycosideruthenium conjugates (2 and 4) were more cytotoxic in the normal cell line than in both cancer cell lines, this tendency was reversed for the guanidinylated conjugate (3), which was much less active in HEK293 than in DU-145 cells.
Cell uptake in DU-145 and HEK293 cell lines
To gain insight into the involvement of the glycoside moiety in the cytotoxic activity of the compounds, the cell uptake of the control ruthenium complex (1) and of the neomycin-ruthenium (2) and guanidinoneomycin-ruthenium (3) As shown in Figure 3 , the intracellular level of ruthenium after exposure to neomycin conjugate 2 (107.14 ± 8.93 pmol Ru/10 6 cells) was substantially higher in the DU-145 cell line than guanidinylated analogue 3 (24.10 ± 0.72 pmol Ru/10 6 cells) was, whereas a similar level was obtained in the HEK293 cell line for both compounds (63.75 ± 8.46
pmol Ru/10 6 cells for 2 and 58.02 ± 3.95 pmol Ru/10 6 cells for 3). On the basis of the amount of intracellular ruthenium after exposure to compounds 1-3, the molar intracellular concentration was calculated by considering the mean cellular volume, as previously reported by Osella et al. 59 The accumulation ratio was obtained from the ratio between the intracellular concentration and the concentration of the compounds in the extracellular medium at the beginning of the incubation period (IC 50 /5). As shown in Table 2 , the accumulation ratio of the neomycin-ruthenium conjugate (2) was similar in both cell lines. However, the accumulation ratio of the guanidinylated analogue (3) was much higher than that of 2 both in the cancer DU-145
cell line (about 3-fold) and in the non-tumorigenic HEK293 cell line (about 4-fold).
Hence, these results are consistent with the generally accepted idea that the incorporation of guanidinium groups in a molecule facilitates its internalization through cell membrane, [60] [61] [62] such as in the case of cell-penetrating peptides. As previously mentioned, cell uptake studies with amino-and guanidinoglycosides had demonstrated an approximately 20-fold internalization enhancement of neomycin upon guanidinylation. 45 In fact, guanidinoneomycin shows similar or even better cell uptake efficiency than some polyarginine-containing peptides, 45, 60, 61, 62 which has been attributed to the semi-rigid pre-organization of the guanidinium groups on the glycoside core. 45 Accordingly, ICP-MS accumulation studies with conjugates 2 and 3 showed the same tendency in both cell lines, since guanidinylation of the neomycin moiety leads to a compound (conjugate 3) with greater accumulation than its amino precursor (conjugate 2). Moreover, it should be noted that accumulation of the guanidinylated analogue (3) is about 1.4-fold higher in the normal cell than in the tumor cell, whereas 2 is accumulated at the same ratio in both cell lines.
Regarding the parent complex (1), as shown in Figure 3 , the intracellular level of ruthenium in DU-145 cells (240.86 ± 84.40 pmol Ru/10 6 cells) was much higher than in HEK293 cells (27.64 ± 2.29 pmol Ru/10 6 cells). Similarly, the accumulation ratio was about 3-fold higher in DU-145 than in HEK293 cells (Table 2) , which indicates higher accumulation in the prostate cancer cell line than in the normal cell line. In consequence, we can conclude that conjugation of the ruthenium complex through the imidazole ligand to a hydrophilic molecule, either neomycin or guanidinoneomycin, leads to compounds (2 and 3) with reduced accumulation in both cell lines, particularly in the case of conjugate 2, since the incorporation of the guanidinium groups in the glycoside moiety seems to ameliorate this reduction.
Finally, the fact that in all cases the intracellular concentrations were greater than the extracellular concentrations indicates an active cell uptake process for all the compounds, particularly in the case of complex 1 and, to a lesser extent, its guanidinoneomycin conjugate 3. Table 2 . Intracellular ruthenium concentrations determined in DU-145 and HEK293 cells after exposure to compounds 1-3 for 24 h at a concentration that was a fifth of their IC 50 value. The volume of a single cell was considered to be about 2 pL. 63 Accumulation ratio 59 Such differences in cytotoxic activity for each compound in a particular cell line, either normal or tumoral, could be interpreted in terms of cell uptake and accumulation efficiency. First, the nature of the aminoglycoside moiety seems to be an important factor, since the cytotoxicity of the neomycin-ruthenium conjugate (2) in the three cell lines is about 2.5-fold higher than that of the neamine-containing conjugate (4).
Although both aminoglycosides are polycations at physiological pH, the greater number of ammonium groups in neomycin than in neamine (six vs four) might favor accumulation of conjugate 2, resulting in a slightly greater antitumoral activity. Second, the fact that the cytotoxicity of the guanidinylated conjugate (compound 3) in the three cell lines is substantially higher than that of the parent aminoglycoside conjugate Table 2 , guanidinylation of the aminoglycoside moiety leads to a compound (3) with higher accumulation than that of its amino precursor 2.
Indeed, the accumulation ratio of 3 in the cancer cell line was about 3-fold greater than that of 2, whereas this tendency increased even more in the normal cell line (about 4-fold). These results indicate that guanidinylation of the amino functions at the aminoglycoside moiety in conjugate 2 had a positive effect on cell uptake, thus improving intracellular accumulation. Moreover, it should be noted that the accumulation ratio of conjugate 3 in the normal cell line was 1.4-fold higher than in the cancer cell line, thus revealing behavior the opposite of its amino precursor 2, which was equally accumulated in both cell lines, or that of control complex 1, which accumulated at a higher proportion (about 3-fold) in DU-145 than in HEK293.
On the one hand, recent studies have revealed that guanidinoneomycin uptake in CHO cells is mediated by cell-surface heparin-sulfate proteoglycans, which has been used to transport large bioactive cargo into cells at low concentration (nM order) in a selective proteoglycan-dependent manner. [47] [48] [49] Thus, we may speculate that differences in the expression level and/or in the composition of proteoglycan receptors on the cell membrane surface between cancer cells and normal cells would be responsible for such differences in the accumulation ratio of 3 between DU-145 and HEK293 cells. 64 On the other hand, the fact that neomycin-and guanidinoneomycin-ruthenium conjugate's accumulations were lower than that of the parent ruthenium complex 1 also indicates that conjugation to polar, polycationic glycosides results in reduced cell uptake in both cell lines, although this reduction was more dramatic in the cancer cell line. It is well known that lipophilic compounds can cross cell membranes more readily than hydrophilic compounds, which results in increased intracellular accumulation. This is also true for ruthenium(II) arene complexes since an increase in their lipophilicity, for example by increasing the size of the arene ligand, correlates with greater cytotoxicity.
therefore diminish cell uptake. Although the lipophilicity provided by the ruthenium complex (e.g. p-cymene and PPh 3 ligands) may modulate the ability of amino(guanidino)glycosides to cross cell membranes when conjugated together, these results seem to indicate that the glycoside moiety, particularly in the case of guanidinoneomycin, has a fundamental weight in the cell uptake of the conjugates.
Overall, on the basis of cytotoxicity and cell uptake studies, in DU-145 cells there is a correlation between accumulation (1 >> 3 > 2) and anti-proliferative activity (1 ≈ 3 >> 2). The same tendency was found in the case of the normal cell line, since the cytotoxic activity ranking (1 > 3 >> 2) follows that of cellular accumulation data (1 > 3 >> 2).
Interestingly, despite the fact that neomycin-ruthenium conjugate (2) accumulation was similar in both cell lines, its anti-proliferative activity was higher in the normal cell than in the tumor cell (about 1.7-fold). An opposite tendency was found for the guanidinylated analogue (3), since the cytotoxic activity was higher in the tumor cell line than in the normal cell line (about 1.8-fold), although the accumulation ratio in the normal cell was slightly higher (about 1.4-fold). These results suggest that the glycoside moiety cannot be seen as a simple carrier that modulates the lipophilicity of the anticancer ruthenium(II) arene complex and, for instance, cell uptake, but rather as a dynamic moiety that also modulates the anti-proliferative activity of the metal fragment, depending on the cell type. Indeed, the fact that the anti-proliferative activity of 3 in the DU-145 cancer cells was higher than in the HEK293 normal cells, with a lower accumulation ratio, suggests that guanidinoneomycin provides some kind of selectivity against cancer cells. This hypothesis is supported by the greater cytotoxicity of ruthenium complex 1 or its neomycin conjugate 2 in normal cells than in cancer cells, despite the fact that their accumulation in normal cells is much lower than (1) or similar to (2) that found in cancer cells. Hence, conjugation to guanidinoneomycin leads to a compound (3) with reduced cytotoxicity against normal cells but with a similar antiproliferative activity to that of the parent ruthenium complex 1 in DU-145 cells.
Finally, we cannot rule out the possibility that amino(guanidino)glycoside conjugation may also modify not only cell uptake in cancer and normal cells, but also the mechanism of action of the ruthenium complex or its biological target. As previously 
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